Shelley Chu bought $200k of ODTX
director at Odyssey Therapeutics, Inc.. 11,111 shares at an average of $18.00, traded May 11, 2026, filed May 11, 2026.
Score components
- +15RoleDirector
- +12Trade size$200k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNo price history yet
- +15Cluster7 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-217589, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 11, 2026 | POpen-market purchase Common Stock | +11,111 | $18.00 | $200k | 11,111 | May 11, 2026 |
Related signals
Other insiders at Odyssey Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 58Moderate | Odyssey Therapeutics, Inc. | Tpg Gp A, LLC other | $25M 1,388,889 shares | +60% | |
| 61Notable | Odyssey Therapeutics, Inc. | Dimension Capital II, L.P. director | $20M 1,111,111 shares | +50% | |
| 53Moderate | Odyssey Therapeutics, Inc. | Sr One Capital Management, LLC owner | $10.0M 555,555 shares | +35% | |
| 17Weak | ODTXsell Odyssey Therapeutics, Inc. | Sr One Capital Management, LLC owner | $32k 1,780 shares | -0% | |
| 37Weak | Odyssey Therapeutics, Inc. | Jason Haas Chief Financial Officer | $20k 1,000 shares | +2% | |
| 40Moderate | Odyssey Therapeutics, Inc. | Jeffrey M Leiden director | $100k 5,000 shares | +2% | |
| 61Notable | Odyssey Therapeutics, Inc. | Nan (LN) Li director | $20M 1,111,111 shares | +50% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.